Coronavirus (COVID-19) Statement

We continue to closely monitor the situation surrounding the COVID-19 pandemic and are following the published recommendations of the CDC and the American Academy of Ophthalmology. We will continue to see our patients and treat any urgent/emergent needs.

With all of our offices open, the following protocols are in place:

1) We have greatly expanded measures to disinfect our office including cleaning between each patient appointment.

2) To limit any potential exposure, we ask you NOT to bring any non-essential person(s) with you to the appointment.

3) If someone must accompany you to your appointment, we ask that they do not enter the office, if at all possible.

4) If you have an upcoming appointment and identify with the following statements, please do not come directly to the office, but instead call us:

• Fever greater than 100.4

• Respiratory symptoms or difficulty breathing

• Exposed to someone with COVID-19 in the past 14 days

• Placed in self/hospital quarantine by medical doctor

 Your health and that of our staff is our guiding priority and we continue to update our protocol to ensure safety for everyone. If you have questions regarding these evolving protocols, please contact our office.

Dr. Batlle CURRICULUM VITAE

Ivan R. Batlle, M.D.
 

WORK HISTORY

April 2009 - PRESENT:

  • Retina Associates, LLC
    Santa Fe Medical Building
    9301 West 74th Street
    Suite 210
    Shawnee Mission, KS 66204
  • Retina Associates, LLC
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. LLC
    4100 North Mulberry Drive
    Suite 100
    Kansas City, MO 64116
  • Retina Associates, LLC
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, LLC
    3700 West 10th Street
    Suite 101
    Sedalia, MO 65301
  • Retina Associates, LLC
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

June 2008 – April 2009:

  • South Texas Retina Consultants, LLP Corpus Christi, TX

2006 – May 2008:

  • Mid-America Retina Consultants, P.A. Kansas City, MO

2004 – 2005:

  • East Jefferson Hospital
    Metairie, LA
    Chairman Department of Ophthalmology
  • Touro Infirmary
    New Orleans, LA
    Chairman Department of Ophthalmology
  • Homesite Medical Director

1999 – December 2005:

  • Retina Associates New Orleans, LA

1997 – 1999:

  • President of Oftalmologia Especializada, A.P.C.
    Santo Domingo, Dominican Republic
  • La Asociacion La Hora de Dios
    Santo Domingo, Dominican Republic
    Director of Ophthalmology

1996 – 1999:

  • President Consultorio Oftalmologico Ozama, A.P.C. Santo Domingo, Dominican Republic

1992 – 1998:

  • Universidad de Puerto Rico Dept. of Ophthalmology
    San Juan, Puerto Rico
    Instructor Basic Sciences Course

1991 – 1996:

  • Vice-President Centro de Microcirugia Ocular y Laser Santo Domingo, Dominican Republic

1990 – 1991:

  • Gitter and Cohen Associate New Orleans, LA

EDUCATION

  • FELLOWSHIP: Medical/Surgical Retina – Touro Infirmary/The Foundation for Retinal Research, 1401 Foucher Street, New Orleans, LA 70115 (July 1, 1986 – June 30, 1990) Fellowship Director: Kurt A. Gitter, M.D.
  • RESIDENCY: Ophthalmology – Bascom Palmer Eye Institute, University of Miami School of Medicine, 900 NW 17th Street, Miami, FL 33136 (July 1, 1986 – June 30, 1989)
  • INTERNSHIP: Medicine – The Alton Ochsner Medical Foundation, Ochsner Clinic, New Orleans E, 5701 Deer Park Blvd, New Orleans, LA 70127 (July 1, 1985 – June 30, 1986)
  • MEDICAL SCHOOL: Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112 (1981-1985)
  • UNDERGRADUATE: Vanderbilt University, 2201 West End Avenue, Nashville, TN 37235 (1977-1981)

MEMBERSHIPS:

  • Fellow American College of Surgeons
  • Fellow American Academy of Ophthalmology
  • Pan-American Association of Ophthalmology
  • New Orleans Academy of Ophthalmology, Program Chairman 2004, Board Member 2004 – Present
  • American Society of Retina Specialists
  • Kansas City Society of Ophthalmology and Otolaryngology Journal Club
  • Kansas City Society of Ophthalmology and Otolaryngology
  • Kansas Society of  Eye Physicians and Surgeons
  • Missouri Society of Eye Physicians and Surgeons
  • Missouri State Medical Association
  • Louisiana Ophthalmology Society
  • Sociedad Dominicana de Oftalmologia, President 1995-1996
  • Santo Domingo Rotary Club, President 1994-1995
  • Patronato Nacional de Ciegos, Vice-President 1995-1998

ACCREDITATIONS

  • American Board of Ophthalmology 1990
  • Louisiana Board of Medical Examiners 1990 – Present
  • Mississippi Board of Medical Licensure 1999 – Present
  • Ministry of Health of the Dominican Republic 1991 – Present

PUBLICATIONS, SPEAKING INVITATIONS AND RESEARCH

  • Periocular Triamcinolone Acetonide as Treatment for Macular Edema Secondary to Branch Vein Occlusion Associated with Retinal Arteriovenous Malformation. Retina:26(9):1079-1080, November 2006
  • Ischemic and Hemorrhagic Retinal Vasculitis Associated with West Nile Virus Infection. Retina: 26(3):365-367, March 2006
  • Guest speaker Fundacion Oftalmologica Nacional, Bogota, Columbia 2005
  • Panelist Pan American Congress of Ophthalmology, Puerto Rico 2003
  • Panelist Pan American Congress of Ophthalmology, Chile 2005
  • Retinal Panel Joint Meeting of the American Academy of Ophthalmology/Pan American Association of Ophthalmology, 2002
  • Speakers Forum, Novartis Pharmaceuticals 2001-2005
  • Clinical and Electrophysiologic Findings in a Family of Homozygous Recessive RP Patients, Ophthalmology 2000
  • Functional and Anatomic Results in the Management of Retinal Detachment, Dominican Ophthalmological Society, 1996 Pan American Congress of Ophthalmology, Cancun, Mexico 1996
  • Vernal Incidence of Central Serous Choroidopathy, Dominican Ophthalmological Society 1995
  • Visual Results of Scleral Fixation Intraocular Lenses, Dominican Ophthalmological Society 1994
  • The Surgical Results in the Management of Advanced Stages of Sickle-Cell Retinopathy, The Vitreous Society 1994
  • Vitamin A Enhancement of Cataract Wound Closure, Annals of Ophthalmology 1988

CLINICAL RESEARCH

  • Alcon:  Principal Investigator, AART C-02-60: Anecortave Acetate Risk Reductions Trial for Patients with Non-Neovascular Age-Related Macular Degeneration.
  • Alcon:  C-98-03, Sub-Investigator,  An Evaluation of Safety and Efficacy of Anecortave Acetate Sterile Suspension (30mg, 15mg, or 3mg) versus Placebo Following Sub-Tenon Injections for the Inhibition of Neovascularization in Patients with Exudative Age-Related Macular Degeneration, 9/1999-11/2001.
  • Alcon: RTH258-C001, Sub-Investigator, Efficacy and Safety of RTH258 versus Aflibercept for Patients with Neovascular Age-Related Macular Degeneration.
  • Alcon: C-12-006, A Prospective, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of ESBA1008 versus EYLEA in Subjects With Exudative Age-Related Macular Degeneration.
  • Alimera Sciences: Principal Investigator, A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 ug/day and ASI-001B 0.2 ug/day Flucinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects With Diabetic Macular Edema.
  • Allergan: BDP 208397-001, A Multi-Center, 2 Stage Single Dose Study of the Safety and Efficacy of AGN-208397 in Patients With Macular Edema Associated with Retinal Vein Occlusion.
  • An Observation Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation, Principal Investigator.
  • AREDS2: Principal Investigator, A Multi-Center, Randomized Trial to Access the Effects of Oral Supplementation of Macular Xanthophyllis (Lutein + ZEAXANTHIN) and/or (Long-Chain Omega-3 Fatty Acids 9DHA) and EPA on the Progression of Advanced Age-Related Macular Degeneration.
  • Collaborative Ocular Melanoma Study (COMS)
  • DRCR: Sub-Investigator, Protocol T, Aflibercept, Bevacizumab and Ranibizumab for the Treatment of Diabetic Macular Edema, 12/2012 - 10/2015.
  • DRCR: Protocol V, Sub-Investigator, Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity, 10/2013 - present.
  • DRCR: Protocol U, Sub-Investigator, Short-Term Evaluation of Combination Corticosteroid + Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy in Pseudophakic Eyes, 06/2014 - present.
  • DRCR: Protocol AA, Sub-Investigator, Peripheral Diabetic Retinopathy Lesions on Ultrawide-Field Fundus Images and Risk of Diabetic Retinopathy Worsening Over Time.
  • DRCR: Protocol W, Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk.
  • Eyetech: EOP1010, Sub-Investigator, An Open-Label, Non-Comparative Protocol for the Use of Pegaptanib Sodium Injection Every 6 Weeks in Patients With Exudative Age-Related Macular Degeneration, 11/2004 - 11/2005.
  • Eyetech: EOP1011, Principal Investigator, A Phase III, Randomized, Dose-Ranging, Double-Masked, Multi-Center Trial, in Parallel Groups to Determine the Safety, Efficacy, and Pharmacokinetics of Intravitreal Injections of Pegaptanib Sodium Compared to Sham Injections for 30 Weeks in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion, 09/2004 - 11/2006.
  • Eyetech:  EOP1004, Sub-Investigator, A Phase II/III, Randomized, Controlled, Double-Masked, Dose-Finding, Multi-Center, Comparative Trial in Parallel Groups to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for Patients with Exudative Age-Related Macular Degeneration, 8/2001-11/2005.
  • Genentech: FVF3192g (PIER), Sub-Investigator,  A Phase III, Multi-Center, Randomized, Double-Masked, Sham Injection Controlled Study of the Efficacy and Safety of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization With or Without Classic CNV Secondary to Age-Related Macular Degeneration. 
  • Genentech: FVF4165g (BRAVO), Sub-Investigator, A Multicenter, Randomized, Double-Masked, Sham Injection Controlled Phase III Study to Assess the Safety and Efficacy of Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. 
  • Genentech: FVF4166g (CRUISE), Sub-Investigator, A Multi-Center, Randomized. Double-Masked, Sham Injection Controlled Phase III Study to Assess the Safety and Efficacy of Ranibizumab for the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion, Sub-Investigator.
  • Genentech: FVF4168g (RIDE), Sub-Investigator, A Phase III, Double-Masked, Multi-Center, Randomized, Sham Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus.
  • Genentech: FVF4579g (HARBOR), Sub-Investigator, A Phase III, Double-Masked, Multi-Center, Randomized, Active Treatment Controlled Study of the Efficacy and Safety of 0.5mg and 2.0mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration.
  • Genentech: FVF4967g (SHORE), Sub-Investigator, A Multi-Center, Randomized Study Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion.
  • Genentech: GX29176 (CHROMA), Sub-Investigator, A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
  • Genentech: GX30191 (OMASPECT), Sub-Investigator, Phase III, Multi-Center, Randomized Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
  • Genentech: GR40548 (ARCHWAY), Principal Investigator, Phase III, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.
  • Genentech: GR40349 (YOSEMITE), Sub-Investigator, Phase III, Double-Masked, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema.
  • Genentech: GR40306 (TENAYA), Sub-Investigator, Phase III, Double-Masked, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Neovascular Age-Related Macular Degeneration.
  • Genentech: GR40549 (PORTAL), Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy.
  • Genentech: GR41675 (PAVILION), Study of the Efficacy, Safety and Pharmacokinetics of the Port Deliver System With Ranibizumab in Patients with Diabetic Retinopathy.
  • ISTA Pharmaceuticals: Protocol Vit-02-0896XX.
  • Lux BioSciences: LX211-11, Sub-Investigator, A Multi-Center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects With Active Noninfectious, Intermediate, Posterior or Pan-Uveitis.
  • Miravant Medical Technologies/Pharmacia & Upjohn: Protocol SnET5-98EA001.
  • MyLan: MYL-1701P-3001, Sub-Investigator, Active-Controlled Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Aflibercept in Subjects With Diabetic Macular Edema.
  • National Eye Institute: SCORE Study, Sub-Investigator, Standard Care versus Corticosteroid for Retinal Vein Occlusion.
  • National Eye Institute: SCORE2, Principal Investigator, Study of Comparative Treatments for Retinal Vein Occlusion.
  • NGM Bio Pharmaceuticals: NGM621-GA-201 (CATALINA): Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
  • Novartis: CRTH258B2301, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema.
  • Novartis: CRTH258AUS04, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab 6mg q4weeks Compared to Aflibercept 2mg q4weeks in Patients With Neovascular Age-Related Macular Degeneration With Persistent Retinal Fluid.
  • Novartis: CRTH258C2301, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion.
  • Novartis: CRTH258C2302, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Central Retinal Vein Occlusion.
  • Novartis: CRTH258B2305, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema.
  • Oculex Pharmaceuticals: DC103-06-002, Principal Investigator, A Phase II, Randomized, Multi-Center, Dose-Ranging, Controlled, Parallel Group Trial to Assess The Safety and Efficacy of a Posterior Segment Drug Delivery System in the Treatment of Persistent Macular Edema, 10/2001 - 06/2003.
  • Ophthotech: OPH1001, Sub-Investigator, A Phase II, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-Peglayted Aptamer) Given in Combination With Lucentis in Subjects With NVAMD.
  • Ophthotech: OPH1003, A Phase III, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista Administered in Combination With Lucentis Compared to Lucentis Monotherapy in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration.
  • Opthea: OPT-302-1002, Principal Investigator, A Dose-Ranging study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone for Patients With Neovascular Age-Related Macular Degeneration.
  • QLT Photos Therapeutics, Inc./Ciba Vision: Verteporfin in ARMD (V.A.M.) Study
  • Regeneron: R2176-3-AMD-1417, Phase II, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With NVAMD.
  • Regeneron: R910-3-DME-1518, Phase II, Randomized, Double-Masked, Active-Controlled, Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With DME.
  • VGFT: OD-0605, Principal Investigator, A Randomized, Double Masked, Active-Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration.

PRESENTATIONS

  • Update on the Treatment of Diabetic Retinopathy 

A Vision to be the Best

As the largest group of Retina specialists in the Greater Kansas City, Topeka, Sedalia and surrounding areas we offer multiple professional offices to serve you.  Each of our offices are staffed and equipped to provide the highest level of health care service and access in a comfortable environment.

Dr. Batlle is currently seeing patients at our Topeka, Shawnee Mission and Overland Park locations.

Retina Associates, PA logo

Retina Associates, LLC

Retina Associates, LLC is an advanced medical practice devoted to the diagnosis and treatment of retinal, macular, and vitreous diseases. Together, our eye care physicians belong to various prestigious organizations: 

  • American Board of Ophthalmology
  • American Academy of Ophthalmology
  • Association for Research in Vision and Ophthalmology
  • American College of Surgeons
  • American Society of Retina Specialists

Our mission is to help every patient preserve or restore their sight through our advanced treatment options. To discuss your needs with one of our doctors, request an appointment online or call us at (913) 831-7400.

Contact Us

Rate, Review & Explore

Social Accounts Sprite
Google map image of our location in 9301 W 74th St Ste 210 Shawnee Mission, KS

Shawnee Mission Office

9301 W 74th St
Ste 210
Shawnee Mission, KS 66204

Closed Today

What is the best time for you?

Add additional time

Tell us a bit about yourself...

(913) 831-7400 Send a message